RU2017128749A3 - - Google Patents

Download PDF

Info

Publication number
RU2017128749A3
RU2017128749A3 RU2017128749A RU2017128749A RU2017128749A3 RU 2017128749 A3 RU2017128749 A3 RU 2017128749A3 RU 2017128749 A RU2017128749 A RU 2017128749A RU 2017128749 A RU2017128749 A RU 2017128749A RU 2017128749 A3 RU2017128749 A3 RU 2017128749A3
Authority
RU
Russia
Application number
RU2017128749A
Other versions
RU2724932C2 (ru
RU2017128749A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITUB2015A003714A external-priority patent/ITUB20153714A1/it
Application filed filed Critical
Publication of RU2017128749A publication Critical patent/RU2017128749A/ru
Publication of RU2017128749A3 publication Critical patent/RU2017128749A3/ru
Application granted granted Critical
Publication of RU2724932C2 publication Critical patent/RU2724932C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2292Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
RU2017128749A 2015-02-09 2016-02-04 Тимозин альфа-1 для применения в лечении муковисцидоза RU2724932C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITRM2015A00056 2015-02-09
ITRM20150056 2015-02-09
ITUB2015A003714A ITUB20153714A1 (it) 2015-09-18 2015-09-18 Timosina alfa 1 per l?uso nel trattamento della fibrosi cistica.
IT102015000053089 2015-09-18
PCT/IT2016/000027 WO2016129005A1 (en) 2015-02-09 2016-02-04 Thymosin alpha 1 for use in treatment of cystic fibrosis

Publications (3)

Publication Number Publication Date
RU2017128749A RU2017128749A (ru) 2019-03-12
RU2017128749A3 true RU2017128749A3 (ru) 2019-08-15
RU2724932C2 RU2724932C2 (ru) 2020-06-26

Family

ID=55661505

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017128749A RU2724932C2 (ru) 2015-02-09 2016-02-04 Тимозин альфа-1 для применения в лечении муковисцидоза

Country Status (11)

Country Link
US (3) US10478474B2 (ru)
EP (2) EP3256150B1 (ru)
JP (3) JP6762524B2 (ru)
KR (1) KR102648036B1 (ru)
CN (1) CN107466236B (ru)
AU (1) AU2016217473B2 (ru)
BR (1) BR112017016205A2 (ru)
CA (1) CA2976062A1 (ru)
ES (1) ES2844578T3 (ru)
RU (1) RU2724932C2 (ru)
WO (1) WO2016129005A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
BR112017016205A2 (pt) 2015-02-09 2018-03-27 Romani Luigina thymosin alpha 1 para uso no tratamento de fibrose cística
CN111494600A (zh) * 2019-06-24 2020-08-07 南京安吉生物科技有限公司 一种药物组合物及治疗免疫力低下疾病的药物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
US8207294B2 (en) * 2003-03-28 2012-06-26 Sciclone Pharmaceuticals, Inc. Treatment of Aspergillus infections with alpha thymosin peptides
WO2006101740A2 (en) * 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
US8017129B2 (en) * 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
WO2009033816A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
AU2011242452A1 (en) * 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
CN102973926A (zh) 2011-11-20 2013-03-20 上海市肺科医院 胸腺肽α1在制备治疗肺纤维化药物中的用途
BR112017016205A2 (pt) 2015-02-09 2018-03-27 Romani Luigina thymosin alpha 1 para uso no tratamento de fibrose cística

Also Published As

Publication number Publication date
BR112017016205A2 (pt) 2018-03-27
RU2724932C2 (ru) 2020-06-26
US11524056B2 (en) 2022-12-13
US10478474B2 (en) 2019-11-19
CA2976062A1 (en) 2016-08-18
WO2016129005A1 (en) 2016-08-18
JP6762524B2 (ja) 2020-09-30
KR102648036B1 (ko) 2024-03-14
EP3865149A1 (en) 2021-08-18
JP2022133412A (ja) 2022-09-13
CN107466236B (zh) 2021-10-26
JP2018511650A (ja) 2018-04-26
US20180036381A1 (en) 2018-02-08
JP7102475B2 (ja) 2022-07-19
ES2844578T3 (es) 2021-07-22
US20200023039A1 (en) 2020-01-23
EP3256150A1 (en) 2017-12-20
AU2016217473A1 (en) 2017-08-24
AU2016217473B2 (en) 2021-07-29
KR20170123628A (ko) 2017-11-08
US20230173031A1 (en) 2023-06-08
RU2017128749A (ru) 2019-03-12
EP3256150B1 (en) 2020-12-09
US12083165B2 (en) 2024-09-10
JP2020196749A (ja) 2020-12-10
CN107466236A (zh) 2017-12-12

Similar Documents

Publication Publication Date Title
RU2017128749A3 (ru)
CN303070995S (ru)
BR0008719B1 (ru)
BR0003751B1 (ru)
BR0003746B1 (ru)
BR0003686B1 (ru)
BR0005085B1 (ru)
BR0003401B1 (ru)
CN303071269S (ru)
CN303070228S (ru)
CN303069958S (ru)
CN303069180S (ru)
BR9816371B1 (ru)
BR0318254B1 (ru)
BR0310120B1 (ru)
BR0306001B1 (ru)
BR0301737B1 (ru)
BR0212367B1 (ru)
BR0003208B1 (ru)
BR0111284B1 (ru)
BR0016834B1 (ru)
BR0003189B1 (ru)
BR0006854B1 (ru)
BR0009994B1 (ru)
BR0009942B1 (ru)

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant